NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
Clinical Trials
20 trialsNCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT06743100 2025-04-02
18F-Floretyrosine Expanded Access Program
Telix Pharmaceuticals (Innovations) Pty Limited
Available
NCT05518838 2024-11-08
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Oblato, Inc.
No longer available
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT05936216 2024-10-01
TVI-Brain-1 in Expanded Access Patient
TVAX Biomedical
No longer available
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT05551013 2024-08-09
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Aveta Biomics, Inc.
No longer available
NCT04321694 2024-04-25
Expanded Access for KHK2455
Kyowa Kirin Co., Ltd.
No longer available
NCT05028166 2024-03-15
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT04599647 2022-06-29
EAP for the Treatment of Glioblastoma With PVSRIPO
Istari Oncology, Inc.
No longer available
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT03259633 2020-05-01
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Approved for marketing
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02961491 2019-01-30
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Approved for marketing
NCT03068650 2017-10-18
CDX-110
Celldex Therapeutics
No longer available
NCT02755987 2016-06-07
Expanded Access to ANG1005 for Individual Patients
Angiochem Inc
No longer available
NCT00730444 2009-11-09
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare
Approved for marketing